The Skin Cancer Drugs Market: 2019 - 2030​ - Opportunities, Challenges, Strategies & Forecasts​

Release Date: August 2019
Number of Pages: 263
Number of Tables and Figures: 45
​
Synopsis: Skin cancer, the uncontrolled growth of abnormal skin cells, is among the most common types of cancer. With the exception of melanoma, most skin cancers are not life threatening. However, early diagnosis and treatment are critical to avoid functional or cosmetic deformities that can result from the invasion and damage of nearby tissues and organs. 

Although surgery is the most common treatment for skin cancer, drugs – including chemotherapy, immunotherapy and targeted agents – are widely used for treating advanced forms of skin cancer. Drug developers are investing heavily in new drug development programs for skin cancer, primarily in the areas of melanoma, BCC (Basal Cell Carcinoma) and SCC (Squamous Cell Carcinoma).  
​
As new drugs continue to revitalize skin cancer treatment options, we expect the skin cancer drugs market to grow at a CAGR of approximately 10% between 2019 and 2022, eventually accounting for over $5.2 Billion by the end of 2022.  
The “Skin Cancer Drugs Market: 2019 – 2030 – Opportunities, Challenges, Strategies & Forecasts” report presents an in-depth assessment of the skin cancer drugs ecosystem including therapeutic areas, treatment options, key trends, market drivers, challenges, investment potential, leading therapies, drug development pipeline, opportunities, future roadmap, value chain, ecosystem player profiles and strategies. The report also presents market size forecasts for skin cancer drugs from 2019 through to 2030. The forecasts are segmented for 3 drug classes, 4 therapeutic categories, 5 regions and 25 leading countries. 

The report comes with an associated Excel datasheet suite covering quantitative data from all numeric forecasts presented in the report, as well as an Excel sheet covering clinical drug development pipeline for the skin cancer market, profiling over 130 future candidates.
​For a Sample and Table of Contents please contact [email protected]

Pricing: The report is available for the following price: 
​
Single User License: USD 2,500

Company Wide License (Single Site): USD 3,500

Company Wide License (Global Site): USD 6,500

Key Findings:
The report has the following key findings:​
  • Drug developers are investing heavily in new drug development programs for skin cancer, primarily in the areas of melanoma, BCC and SCC. These three indications collectively constitute more than 80% of all drug development programs for skin cancers. 
  • As new drugs continue to revitalize skin cancer treatment options, we expect the skin cancer drugs market to grow at a CAGR of approximately 10% between 2019 and 2022, eventually accounting for over $5.2 Billion by the end of 2022. 
  • Immunotherapies – primarily monoclonal antibodies – are continuing to gain a strong foothold in the skin cancer drugs market with a number of recent approvals such as anti-PD-L1 antibody Pembrolizumab (Keytruda) which was already being marketed for melanoma is now approved for multiple skin conditions including SCC & MCC, and anti-PD-1 antibody Cemiplimab (Libtayo) for SCC. 
  • A major focus of late-stage drug development programs is on monoclonal antibodies, IDO1 inhibitors, BRAF and MEK inhibitors, TKIs (Tyrosine Kinase Inhibitors), and oncolytic viruses and vaccines. 
  • Increasing number of companies are vying for market share of the skin cancer market by investing into promising pipeline candidates, innovating new combination therapies whereas major players are looking to solidify their position in the ecosystem with M&A deals, recent examples being Pfizer’s acquisition of Array BioPharma and Bristol-Myers Squibb acquisition of Celgene.  

Topics Covered:
The report covers the following topics:  
  • Skin cancer drugs ecosystem 
  • Market drivers and barriers 
  • Review of melanoma and non-melanoma skin cancers  
  • Role of drugs in skin cancer and key trends 
  • Analysis of key drug classes and 30 plus leading skin cancer drugs 
  • Future drug development pipeline with more than 130 candidates 
  • Industry roadmap and value chain 
  • Profiles and strategies of 100 leading ecosystem players, including skin cancer drug developers 
  • Strategic recommendations for ecosystem players 
  • Market analysis and forecasts from 2019 till 2030 

Forecast Segmentation:
Market forecasts are provided for each of the following submarkets and their subcategories:
  • Drug Class
    • Chemotherapy 
    • Immunotherapy 
    • Targeted Agents & Other Drugs 
  • Therapeutic Category
    • Melanoma 
    • BCC/SCC (Basal and Squamous Cell Carcinoma) 
    • MCC (Merkel Cell Carcinoma) 
    • Other Skin Cancers 
  • Regional Markets
    • ​Asia Pacific
    • Europe
    • Middle East & Africa
    • North America
    • Latin & Central America
  • Country Markets
    • Brazil 
    • Canada 
    • China 
    • Egypt 
    • France 
    • Germany 
    • Greece 
    • India 
    • Israel 
    • Italy 
    • Japan 
    • Mexico 
    • Netherlands 
    • Poland 
    • Portugal 
    • Russia 
    • Saudi Arabia 
    • South Africa 
    • South Korea 
    • Spain 
    • Switzerland 
    • Taiwan 
    • Turkey 
    • UK 
    • USA 

Key Questions Answered:
The report provides answers to the following key questions:
  • How big is the skin cancer drugs opportunity? 
  • What trends, challenges and barriers are influencing its growth? 
  • How is the ecosystem evolving by segment and region? 
  • What will the market size be in 2022 and at what rate will it grow? 
  • Which countries and submarkets will see the highest percentage of growth? 
  • What does drug development pipeline look like in 2019 for skin cancer? 
  • What are the prospects of immunotherapy drugs in skin cancer treatment? 
  • How big is the market for melanoma drugs? 
  • Who are the key market players and what are their strategies? 
  • How will patent expirations of innovator drugs impact the market? 
  • What strategies should skin cancer drug developers adopt to remain competitive? 

List of Companies Mentioned:
The following companies and organizations have been reviewed, discussed or mentioned in the report:
AB Science
AbbVie
Adaptimmune Therapeutics
Adgero Biopharmaceuticals
Agenus
Almirall
Altor Bioscience
Amgen
Angimmune
Antigen Express
APCure
Apexigen
Array BioPharma
Ascend Biopharmaceuticals
Astex Pharmaceuticals
AstraZeneca
Athenex
Autotelic
Basilea Pharmaceutica
Berg
BioLineRx
Bioniz
Biosceptre
Biothere Pharmaceuticals
BMS (Bristol-Myers Squibb)
Boehringer Ingelheim
Boston Biomedical
Brickell Biotech
BrightPath Biotherapeutics
Caladrius Biosciences
Celgene Corporation
Celldex Therapeutics
CEL-SCI Corporation
Checkmate Pharmaceuticals
Cipla
CK Life Sciences
Cutanea Life Sciences
Cytori Therapeutics
CytRx Corporation
Daiichi Sankyo
DFB Soria LLC
Dr. Reddy’s Laboratories
Dynavax Technologies
Eisai
Eli Lilly and Company
Elios Therapeutics
EMA (European Medicines Agency)
Exelixis
Fresenius Kabi
G&E Herbal Biotechnology
Galderma
Galectin Therapeutics
Genentech
Generex Biotechnology Corporation
Glycotope
GSK (GlaxoSmithKline)
HedgePath Pharmaceuticals
Hikma Pharmaceuticals
Huya Bioscience
Idera Pharmaceuticals
Ignyta
Immune Design
Immunocore
Incyte Corporation
Infinity Pharmaceuticals
Innate Pharma
Inovio Pharmaceutical
Institut Mérieux
Iovance Biotherapeutics
Ipsen
IRX Therapeutics
Jiangsu Hengrui Medicine Co
Johnson & Johnson
Karyopharm Therapeutics
Kowa 
Leap Therapeutics
LEO Pharma
Lilly
LSK BioPharma
Lupin
MacroGenics
Mayne Pharma Group
Meda Pharmaceuticals
MedImmune
Medivir
Merck & Co.
Merck KGaA
Millennium Pharmaceuticals
miRagen Therapeutics
Mirati Therapeutics
Moderna Therapeutics
Molecular Templates
Morphotek
Mylan
NanoCarrier
Nanology
NantCell
NantKwest
Nektar Therapeutics
Neon Therapeutics
Nestlé Health Science
Nestlé Skin Health
Neumedicines
NewLink Genetics
Novartis
Oncolys Biopharma
Oncolytics Biotech
OncoSec Medical
Oncotelic
Ono Pharmaceutical Company
Orbis Health Solutions
Otsuka Holdings Company
Otsuka Pharmaceutical Company
PellePharm
Perseus Holdings USA
Pfizer
Philogen
Phio Pharmaceuticals
Pierre Fabre (Laboratoires Pierre Fabre)
Plexxikon
Polaris Pharmaceuticals
Polynoma
Prometheus Laboratories
Provectus Biopharmaceuticals
Reata Pharmaceuticals
Regeneron Pharmaceuticals
Rhizen Pharmaceuticals
Roche Holding (F. Hoffmann-La Roche)
Sanofi
Sanofi Genzyme
Seattle Genetics
Sesen Bio
Soligenix
Sumitomo Dainippon Pharma
Sun Pharma (Sun Pharmaceutical Industries)
Syndax Pharmaceuticals
Taiho Pharmaceutical Company
Takara Bio
Takeda Oncology
Takeda Pharmaceutical Company
Targovax
Teva Pharmaceutical Industries
Transgene
Trillium Therapeutics
U.S. FDA (Food and Drug Administration)
Ultimovacs
Valeant Pharmaceuticals
Vidac Pharma
Viralytics
X4 Pharmaceuticals